Prof. Kenneth Chapman (University of Toronto, Canada) presented this post-hoc analysis of the ASCENT-COPD study. The study included 3,589 participants; 35.4% (n=1,269) of whom used beta-blockers at baseline and 64.6% (n=2,320) of whom did not. Participants were randomly assigned 1:1 to twice daily aclidinium or placebo, both of which were administered by a dry powder inhaler for ≤3 years. Among beta-blocker users, 627 used aclidinium and 642 used a placebo; whereas among beta-blocker nonusers, 1,164 used aclidinium and 1,156 used a placebo. Outcomes included time to first MACE and all-cause mortality within the 3-year period, rate of moderate-to-severe COPD exacerbation, time to first moderate-to-severe COPD exacerbation within the first year, and change in morning trough forced expiratory volume in 1 second (FEV1) from baseline between weeks 4 and 52. More men than women (64.4% vs 55.5%) used beta-blockers and had ≥1 previous cardiovascular event (67.9% vs 36.7%); otherwise, characteristics at baseline did not differ significantly.
Beta-blocker users and nonusers did not experience significantly different treatment effects on MACE or all-cause mortality, nor did those receiving aclidinium vs placebo. However, aclidinium was associated with longer time to first moderate-or-severe COPD exacerbation in both beta-blocker users and nonusers and a reduction in exacerbation rate (25% and 21% reduction, respectively). Patients who used beta-blockers and aclidinium bromide also showed more improvement in morning trough FEV1 than nonusers using aclidinium bromide (99 mL; 95% CI, 76-122 vs 69 mL; 95% CI, 52-86, respectively; P=0.041).
Prof. Chapman concluded that “aclidinium bromide treatment did not increase the risk of MACE or all-cause mortality vs placebo in patients with moderate-to-very severe COPD and cardiovascular risk factors, regardless of baseline beta-blocker use. Aclidinium reduced the rate of moderate/severe COPD exacerbations, prolonged the time to first COPD exacerbation, and improved lung function vs placebo irrespective of beta-blocker use.”
- Chapman KR et al. Aclidinium bromide treatment in patients receiving beta-blockers: effects on MACE, moderate/severe COPD exacerbations, and lung function in patients with moderate-to-very severe COPD and cardiovascular risk factors (ASCENT-COPD). A2443. ATS 2019, 17-22 May, Dallas, USA.
Posted on
Previous Article
« Long-term safety and efficacy of recombinant human pentraxin-2 in patients with idiopathic pulmonary fibrosis Next Article
Treatable traits in chronic inflammatory airway disease: back to basics »
« Long-term safety and efficacy of recombinant human pentraxin-2 in patients with idiopathic pulmonary fibrosis Next Article
Treatable traits in chronic inflammatory airway disease: back to basics »
Table of Contents: ATS 2019
Featured articles
Letter from the Editor
Interview with Prof. Christian Bergmann
Treatable Traits in Chronic Inflammatory Airway Disease: Back to Basics
Treatable traits in chronic inflammatory airway disease: back to basics
Critical Care Medicine
Distinguishing between 4 different subtypes of sepsis sets the stage for individualised treatment
Stem cell therapy in acute respiratory distress syndrome improves 28-day mortality
SPICE III trial: Early sedation with dexmedetomidine in critically ill patients
SAATELLITE trial: Suvratoxumab prevents ventilator-associated Staphylococcus Aureus pneumonia in intensive care unit patients
Sleep Medicine
Million-patient study reveals gaps in long-term adherence among various sub-populations
Sleep apnoea severity has a non-linear relationship with acute myocardial infarction risk
Obstructive sleep apnoea affects morning spatial navigational memory processing in asymptomatic older individuals
Pulmonary Vascular Disease and Interstitial Lung Disease
Nintedanib reduces lung function decline in systemic sclerosis-associated ILD
Pulmonary arterial hypertension: early treatment with selexipag most effective
Long-term safety and efficacy of recombinant human pentraxin-2 in patients with idiopathic pulmonary fibrosis
Infection
Dupilumab improves outcomes in patients with severe chronic rhinosinusitis with nasal polyps and comorbid asthma
Durability of culture conversion in patients receiving ALIS for treatment-refractory MAC lung disease
E-cigarette use disrupts normal immune response to viral infections, particularly in women
Paediatric Pulmonary Medicine
Bacterial pneumonia predicts ongoing lung problems in infants hospitalised for acute respiratory failure
Aspergillus and early cystic fibrosis lung disease: does it need to be treated?
COPD
CORTICO-COP trial: eosinophil-guided therapy reduces systemic corticosteroid exposure
A randomised controlled trial of a smoking cessation smartphone application
Benralizumab does not ameliorate COPD exacerbations (GALATHEA/TERRANOVA trials)
Aclidinium bromide delays COPD exacerbation without increased MACE risk
Bench-to-Bedside (Pre-Clinical)
Human lung organoids to study foetal RSV infection
CRISPR/Cas9 genome editing therapy of hereditary pulmonary alveolar proteinosis
Cilia diagnostics in primary ciliary dyskinesia
Tuberous sclerosis complex 2 may be a novel target in pulmonary arterial hypertension therapy
Related Articles
November 9, 2021
Persistent fatigue following COVID-19
October 29, 2020
COVID-19 survivors benefit from structured follow-up
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy